

Provided by:



## **Acute Leukemia and Myeloid Neoplasms Case Conference 2023-2024**

**Acute Leukemia and Myeloid Neoplasms Case Conference 2023-2024 - 10/4/2023**

**October 4, 2023**

**12:00 PM - 1:00 PM**

**Perelman Center for Advanced Medicine, Conference Room 12-122**

### **Target Audience**

This program has been designed for Internal Medicine - Hematology, Internal Medicine - Medical Oncology, Pathology-Anatomic/Pathology-Clinical

### **Series Educational Objectives**

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss the importance of adequate marrow cellularity. Tracking technique of marrow. Involvement if pathology in educational series.
- 1 Describe and identify appropriate prophylactic therapies required for patients receiving therapy for acute leukemia.
- 2 Review the standard of care treatment, medications, concomitant medications, risks, benefits and potential toxicities or how to find out/whom to ask.

### **Accreditation**

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For more information, please contact  
Tamieshia Nixon, Julie Mcdaniel, Michele Bloovman  
(215) 662-4074, (267) 970-8367, (215) 662-3191  
Tamieshia.Nixon@pennmedicine.upenn.edu, mcdjulie@upenn.edu,  
michele.bloovman@pennmedicine.upenn.edu

**Check your transcript online at <https://upenn.cloud-cme.com>**

## Designation of Credit

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **ABIM MOC:** up to 1 MOC points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

### **ABPath MOC:** up to 1 MOC points

This activity has been registered to offer credit toward the American Board of Pathology's (ABPath) Continuing Certification program. Physicians can earn up to 1.00 Lifelong Learning credits through ABPath.

**Nurses:** This activity is for 1.00 contact hours.

**Pharmacists:** This activity is approved for 1.00 contact hours

UAN Number: JA0000324-0000-23-003-L04-P

**PAs:** Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for 1.00 AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

**Approved for (PSRM) patient safety/risk management designation**

### **Acknowledgement of Commercial Support\***

None

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provide products or services that may be relevant to the content of this continuing education activity. For this purpose, we consider relationships of the person involved to include financial relationships of a spouse or partner.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain relationships that created a conflict of interest relevant to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity. Any peer reviewer with a potential conflict of interest will recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Alison W Loren	Other Planning Committee Member	Nothing to disclose - 06/20/2023
Alexander E Perl, MD	Other Planning Committee Member	Consulting Fee-AbbVie, Inc.   Advisor-Immunogen (Relationship has ended)   Advisor-BerGenBio (Relationship has ended)   Advisor-Actinium (Relationship has ended)   Consulting Fee-Astellas   Consulting Fee-Foghorn   Advisor-Bristol-Myers Squibb (Relationship has ended)   Advisor-Genentech   Consulting Fee-Daiichi Sankyo   Advisor-Loxo (Relationship has ended)   Advisor-Syndax (Relationship has ended)   Consulting Fee-Sumitomo Dainippon (Relationship has ended)   Consulting Fee-Forma (Relationship has ended)   Consulting Fee-Leukemia and Lymphoma Society/BeatAML LLC   Grant or research support-AbbVie, Inc.   Grant or research support-Astellas   Grant or research support-Daiichi Sankyo   Grant or research support-Syndax   Grant or research support-FujiFilm (Relationship has ended) - 02/09/2023
Noelle V. Frey, MD, MSCE	Other Planning Committee Member	Consulting Fee-Kite Pharma (Relationship has ended)   Consulting Fee-Sana Biotechnology

		(Relationship has ended) - 01/19/2023
Selina Luger, MD	Other Planning Committee Member	Honoraria-Bristol-Myers Squibb (Relationship has ended)  Honoraria-Celgene Corporation (Relationship has ended)  Membership on Advisory Committees or Review Panels, Board Membership, etc.-Marker - 02/06/2023
Heather DiFilippo, CRNP	Other Planning Committee Member	Nothing to disclose - 06/06/2023
Jacqueline Smith, CRNP	Other Planning Committee Member	Nothing to disclose - 11/29/2022
Elizabeth Hexner, MD	Other Planning Committee Member	Grant or research support-Tmunity Therapeutics  Advisor-AbbVie, Inc.  Membership on Advisory Committees or Review Panels, Board Membership, etc.-Blueprint Medicines  Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pharmessentia (Relationship has ended)  Membership on Advisory Committees or Review Panels, Board Membership, etc.-American Board of Internal Medicine - 06/21/2023
Mary Ellen Martin, MD	Other Planning Committee Member	Nothing to disclose - 01/27/2023
Linda Perry, PA-C	Other Planning Committee Member	Paid consultant-Kadmon (Relationship has ended)  Speakers Bureau-Sanofi Genzyme  Paid consultant-Sanofi Genzyme  Speakers Bureau-AbbVie, Inc. (Relationship has ended)  Paid consultant-Incyte Corporation  Speakers Bureau-Incyte Corporation - 01/10/2023
Kim A Hummel, RN	Other Planning Committee Member	Nothing to disclose - 06/06/2023
Shannon R. Mccurdy, MD	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb (Relationship has ended) - 05/11/2023
Jennifer J.D. Morrisette, PhD	Other Planning Committee Member	Honoraria-Novartis (Advanced Health Media) (Relationship has ended)  Advisor-AbbVie, Inc. (Relationship has ended)  Honoraria-Bayer (Relationship has ended)  Stocks or stock options, excluding diversified mutual funds of a publicly traded company-ThermoFisher - 07/05/2023
Adam Bagg, MD	Co-Director, Faculty	Nothing to disclose - 09/29/2023
Martin Carroll, MD	Other Planning Committee Member	Consulting Fee-Janssen Pharmaceuticals (J&J)  Paid consultant-Cartography - 02/13/2023
Saar Gill, MD	Other Planning Committee	Consulting Fee-Hemogenyx  Grant or

	Member	research support-Interius  Grant or research support-Carisma - 05/25/2023
Colleen R Kucharczuk	Nurse Planner	Nothing to disclose - 06/07/2023
Alison Carulli, PharmD	Pharmacy Planner	Nothing to disclose - 06/28/2023
Keith Pratz, MD	Course Director	Advisor-AbbVie, Inc.   Advisor-Bristol-Myers Squibb (Relationship has ended)   Advisor-Novartis / Amgen (Relationship has ended)   Advisor-Jazz Pharmaceuticals (Relationship has ended)   Advisor-Astellas (Relationship has ended)   Advisor-Astra Zeneca Pharmaceuticals (Relationship has ended)   Advisor-Roche (Relationship has ended) - 01/31/2023
Matthew Connor, MD	Other Planning Committee Member	Nothing to disclose - 05/15/2023
Ximena Jordan Bruno, MD	Other Planning Committee Member	Nothing to disclose - 02/08/2023
Catherine Lai, MD , MPH	Other Planning Committee Member	Advisor-Genentech   Advisor-Rigel   Advisor-Taiho Oncology (Relationship has ended)   Advisor-AbbVie, Inc.   Advisor-Novartis (Relationship has ended)   Consulting Fee-Jazz Pharma (Relationship has ended)   Advisor-Pfizer, Inc. (Relationship has ended)   Consulting Fee-PDS Biotechnology   Consulting Fee-Macrogenics (Relationship has ended)   Consulting Fee-Astellas (Relationship has ended)   Speakers Bureau-Jazz Pharma (Relationship has ended)   Speakers Bureau-Astellas (Relationship has ended)   Honoraria-OncLive (Relationship has ended)   Honoraria-BioAscent (Relationship has ended)   Advisor-Daiichi (Relationship has ended) - 05/14/2023
Sriram Anbil, MD	Other Planning Committee Member	Nothing to disclose - 08/30/2023
Minh Than, MD, PhD	Other Planning Committee Member	Nothing to disclose - 06/28/2023
Putzer Hung, MD, PhD	Other Planning Committee Member	Nothing to disclose - 08/30/2023
Shannon Ugarte, MD	Other Planning Committee Member	Nothing to disclose - 08/30/2023
Eleanor P Taranto, MD	Other Planning Committee Member	Nothing to disclose - 08/30/2023
Jacob B Reibel, MD	Other Planning Committee Member	Nothing to disclose - 08/08/2023

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding

diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected